Get the Stockscreener App
36.78
1.23%
-0.62
Vera Therapeutics Inc stock is currently priced at $36.78, with a 24-hour trading volume of 118.46K.
It has seen a -1.23% decreased in the last 24 hours and a -9.62% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $37.55 pivot point. If it approaches the $36.67 support level, significant changes may occur.
Previous Close:
$37.40
Open:
$36.54
24h Volume:
118.46K
Market Cap:
$2.05B
Revenue:
-
Net Income/Loss:
$-94.30M
P/E Ratio:
-10.95
EPS:
-3.36
Net Cash Flow:
$-99.72M
1W Performance:
-4.05%
1M Performance:
-9.62%
6M Performance:
+150.95%
1Y Performance:
+176.70%
1D Range:
$36.45
$37.26
52W Range:
$9.24
$50.78
Vera Therapeutics Inc Stock (VERA) Company Profile
Name
Vera Therapeutics Inc
Sector
Industry
Phone
650-770-0077
Address
170 Harbor Way, 3rd Floor, South San Francisco
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-24 | Initiated | Oppenheimer | Outperform |
| Jan-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-23 | Initiated | Raymond James | Outperform |
| Nov-10-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-16-23 | Initiated | Guggenheim | Buy |
| Jan-04-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-04-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-12-22 | Initiated | JP Morgan | Overweight |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-22 | Initiated | Wedbush | Outperform |
View All
Vera Therapeutics Inc Stock (VERA) Latest News
Vera Therapeutics (NASDAQ:VERA) Shares Gap Down to $38.00 - MarketBeat
MarketBeat
Schroder Investment Management Group Acquires Shares of 1,110,960 Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
MarketBeat
Schroder Investment Management Group Takes $17.09 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Defense World
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
GlobeNewswire Inc.
It is Poised to be a Bull Market for Vera Therapeutics Inc (VERA) – Sete News - SETE News
SETE News
Vera Therapeutics Inc [VERA] Investment Appeal on the Rise – Knox Daily - Knox Daily
Knox Daily
Vera Therapeutics Inc Stock (VERA) Financials Data
Vera Therapeutics Inc (VERA) Net Income 2024
VERA net income (TTM) was -$94.30 million for the quarter ending March 31, 2024, a +7.58% increase year-over-year.
Vera Therapeutics Inc (VERA) Cash Flow 2024
VERA recorded a free cash flow (TTM) of -$99.72 million for the quarter ending March 31, 2024, a -17.44% decrease year-over-year.
Vera Therapeutics Inc (VERA) Earnings per Share 2024
VERA earnings per share (TTM) was -$2.05 for the quarter ending March 31, 2024, a +40.58% growth year-over-year.
Vera Therapeutics Inc Stock (VERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
May 16 '24 |
Sale |
42.32 |
20,651 |
873,890 |
51,206 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
May 15 '24 |
Option Exercise |
3.94 |
8,221 |
32,387 |
61,392 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
May 15 '24 |
Sale |
42.27 |
10,186 |
430,546 |
51,206 |
| Young Joseph R | SVP, FINANCE, CHIEF ACCT OFFCR |
Apr 10 '24 |
Sale |
40.00 |
5,714 |
228,560 |
53,171 |
| Grant Sean | CHIEF FINANCIAL OFFICER |
Apr 03 '24 |
Option Exercise |
14.87 |
99,828 |
1,484,442 |
166,165 |
| Grant Sean | CHIEF FINANCIAL OFFICER |
Apr 03 '24 |
Sale |
39.61 |
99,828 |
3,954,516 |
66,337 |
| Grant Sean | CHIEF FINANCIAL OFFICER |
Apr 03 '24 |
Sale |
39.42 |
18,649 |
735,205 |
0 |
| Katabi Maha | Director |
Mar 25 '24 |
Sale |
40.50 |
340,000 |
13,770,000 |
2,793,987 |
| Katabi Maha | Director |
Mar 22 '24 |
Sale |
40.51 |
413,450 |
16,748,860 |
3,133,987 |
| Katabi Maha | Director |
Mar 21 '24 |
Sale |
44.20 |
81,009 |
3,580,723 |
3,547,437 |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
0.66%
0.84%
Cap:
|
Volume (24h):